Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | survival of motor neuron 2, centromeric | Starlite/ChEMBL | No references |
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Echinococcus multilocularis | survival motor neuron protein 1 | Get druggable targets OG5_132873 | All targets in OG5_132873 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.4527 | 0.4527 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0286 | 0.6918 | 0.6918 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.2742 | 0.2742 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.039 | 1 | 1 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.0149 | 0.2895 | 0.5 |
Brugia malayi | Iron-sulfur cluster assembly accessory protein | 0.0058 | 0.0204 | 0.0204 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.039 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0162 | 0.3276 | 0.3276 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.039 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0286 | 0.6918 | 0.6918 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.039 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0286 | 0.6918 | 0.6918 |
Mycobacterium leprae | PROBABLE ADENOSYLMETHIONINE-8-AMINO-7-OXONONANOATE AMINOTRANSFERASE BIOA | 0.0149 | 0.2895 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0162 | 0.3276 | 0.3276 |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.0149 | 0.2895 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.039 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.4527 | 0.4527 |
Schistosoma mansoni | hypothetical protein | 0.0111 | 0.176 | 0.176 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0162 | 0.3276 | 0.3276 |
Loa Loa (eye worm) | hypothetical protein | 0.0111 | 0.176 | 0.176 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.039 | 1 | 1 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.0149 | 0.2895 | 0.5 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.0149 | 0.2895 | 0.5 |
Echinococcus granulosus | geminin | 0.0205 | 0.4527 | 0.4527 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0111 | 0.176 | 0.176 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.2742 | 0.2742 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0286 | 0.6918 | 0.6918 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.2742 | 0.2742 |
Schistosoma mansoni | survival motor neuron protein | 0.0058 | 0.0204 | 0.0204 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0162 | 0.3276 | 0.3276 |
Mycobacterium ulcerans | hypothetical protein | 0.0149 | 0.2895 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.039 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0058 | 0.0204 | 0.0204 |
Echinococcus multilocularis | geminin | 0.0205 | 0.4527 | 0.4527 |
Onchocerca volvulus | 0.0058 | 0.0204 | 0.5 | |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.039 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.9811 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 4.4668 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of D3 Dopamine Receptor Agonist: D3 Dopamine Receptor B-arrestin Agonist Confirmatory Assay. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (binding) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.